SCHOTT Pharma Releases Q3 Figures, Increases 2026 Forecast

SCHOTT Pharma AG & Co. KGaA has unveiled preliminary figures for the third quarter of 2026, posting an anticipated constant-currency revenue growth of approximately 8% and an EBITDA margin of 27%. This exceeds market expectations of 3.5% revenue growth and a 27.5% EBITDA margin as per the Vara Consensus dated July 6, 2026.

For the fiscal year 2026, SCHOTT Pharma has adjusted its constant-currency revenue growth forecast to a range of 5% to 6% from the previous 2% to 5%. The anticipated EBITDA margin is now 27% to 28%, up from around 27%. This revised guidance surpasses the current market forecast of 3.2% revenue growth and a 27.2% EBITDA margin.

The updated guidance is attributed to robust business performance and a significant agreement with a key customer concerning glass syringes, impacting future revenue. SCHOTT Pharma plans to release its detailed Q3 quarterly statement on August 12, 2026.